A possible mechanism of impaired NK cytotoxicity in cancer patients: down-regulation of DAP10 by TGF-beta 1
- Authors
- Lee, June-Chul; Lee, Kyung-Mi; Ahn, Yong-Oon; Suh, Beomseok; Heo, Dae Seog
- Issue Date
- May-2011
- Publisher
- SAGE PUBLICATIONS LTD
- Keywords
- human NK cells; NKG2D; TGF-beta; DAP10; tumor immunity
- Citation
- TUMORI J, v.97, no.3, pp 350 - 357
- Pages
- 8
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- TUMORI J
- Volume
- 97
- Number
- 3
- Start Page
- 350
- End Page
- 357
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/13483
- ISSN
- 0300-8916
2038-2529
- Abstract
- Aims and background. Elevated TGF-beta 1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. However, the molecular mechanism of immunosuppression by TGF-beta 1 is not yet clarified. Methods. IL-2-activated human NK cells were cultured with TGF-beta 1. Protein levels of NKG2D and DAP10 were examined by FAGS or immunoblot analyses. Real-time RTPCR was performed to quantify the transcription levels. MAPK inhibitors were used to investigate intracellular signaling. Results. TGF-beta 1 down-regulated total and surface NKG2D, which was partially dependent on transcriptional regulation. TGF-beta 1 treatment of human NK cells resulted in significant changes in both transcriptional and translational levels of DAP10. Moreover, treatment with bafilomycin A1 or folimycin restored total NKG2D levels in TGF-beta 1-treated NK cells. The impaired NKG2D down-modulation by TGF-beta 1 was not associated with activation of the MAPK signaling pathway. Conclusions. TGF-beta 1 down-modulates surface NKG2D expression by controlling the transcriptional and translational levels of DAP10.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 1. Basic Science > Department of Biochemistry and Molecular Biology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.